In this issue:
Multivariate models to identify optimal biologic therapy for individual patients
Psoriatic disease and cardiovascular risk in a multiracial population
Oral tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis
Serum homocysteine levels in patients treated with methotrexate
Treatment patterns in patients with psoriasis
Topical therapy for mild-to-moderate plaque psoriasis
Clinical characteristics of pustulotic arthro-osteitis
Drug survival with IL-17 and IL-23 inhibitors for psoriasis
Early- and late-onset psoriatic systemic inflammatory comorbidities
Anti-TNF biosimilars in paediatric and geriatric populations
Please login below to download this issue (PDF)